Should you invest in Bicara Therapeutics Inc? Click for more on BCAX's promising cancer treatment, but proceed with caution ...

Dr. Zocca continued, “Our T-win platform generates off-the-shelf therapeutic cancer vaccine candidates with a unique mechanism of action, capable of both ... IO102-IO103 in combination with KEYTRUDA ® ...

The combination of NUC-3373 plus pembrolizumab was generally well tolerated ... to have two Phase 2 product candidates in our portfolio, each with a distinct mechanism of action, that can potentiate ...

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

Scientists have discovered the mechanism which allows the superbug Methicillin Resistant Staphylococcus aureus (MRSA) to become highly resistant to antibiotics, paving the way for new approaches to ...

Every product was carefully curated by an Esquire editor. We may earn a commission from these links. Here’s how we test products and why you should trust us.

aDepartment of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, Netherlands bDepartment of Medical Oncology, Erasmus University Medical Centre, Rotterdam, Netherlands ...

Adding pembrolizumab to adjuvant chemotherapy in the first-line setting improved disease-free survival (DFS) in patients with high-risk endometrial cancer who have mismatch repair–deficient ...

That’s the worldwide sales figure of a single drug called Keytruda (its generic name is pembrolizumab ... For all cancers, Keytruda’s mechanism of action or the way it works is simple and yet ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

Ivonescimab reduced the risk of disease progression or death by 49% compared with pembrolizumab in patients with PD-L1–positive advanced non–small cell lung cancer. Ivonescimab reduced the risk of ...